Citations

Institution: Mayo Clinic Clear

Showing 10 of 108094 citations.

A proposed clinical guide to delivering Lower Extremity Extracorporeal Distal Revascularization (LEEDR) as a bridge to definitive care in acute limb ischemia
Dvir, May , Jodłowski, Grzegorz , Stonko, David P. , Nelson, Jack, Morrison, Jonathan J. , Treffalls, Rebecca, Morrison, Jonathan J , Stonko, David P , Treffalls, Rebecca N. , Nelson, Jack, Walker, Patrick F.

Perfusion | July 25, 2025 | Volume: 41 | Issue: 3 | Pages: 254-259

10.1177/02676591251363374 | PMID 40708295 Get It

Introduction Lower Extremity Extracorporeal Distal Revascularization (LEEDR) is a novel, preclinically tested technique designed to provide temporary limb perfusion in cases of acute limb ischemia when immediate revascularization is not feasible. Methods LEEDR employs an extracorporeal pump and circuit to draw arterial blood from a proximal inflow site and deliver it to an outflow artery within the ischemic limb. The system is designed for bedside initiation using percutaneous access. Results ALI from embolism, thrombosis, or trauma rapidly leads to irreversible tissue damage. Delays in revascularization are associated with high rates of limb loss and systemic complications. LEEDR offers a time-sensitive intervention aimed at mitigating these risks and preserving limb viability until definitive treatment is available. Conclusion LEEDR is a promising temporary perfusion strategy for limb salvage in ALI. This manuscript outlines its procedural components, technical considerations, and anticipated role in bridging patients to definitive revascularization.
Comparative Effectiveness Research Using Randomized Trials and Observational Studies: Validity and Feasibility Considerations
Bikdeli, Behnood , Bukhari, Syed , You, Seng Chan , Wallach, Joshua D. , Lip, Gregory Y H , Wallach, Joshua D , Ross, Joseph S. , Jeffery, Molly Moore , Cohen, David Jonathan , Januzzi, James Louis

Thrombosis and Haemostasis | July 24, 2025 | Volume: 126 | Issue: 04 | Pages: 335-345

10.1055/a-2664-7887 | PMID 40719151 Get It

Abstract In comparative effectiveness research (CER), ensuring internal, construct, and external validity is crucial. Internal validity determines whether observed outcomes are causally linked to an intervention; construct validity assesses whether a study measures what it intends to; and external validity relates to generalizability in routine practice. Double-blind randomized trials optimize internal validity by minimizing bias and confounding, while construct validity is strengthened through pre-specified protocols and standardized data collection. However, controlled conditions limit external validity. Pragmatic RCTs improve generalizability but may compromise internal validity due to open-label designs. Observational CER studies—including observational studies following the target trial emulation framework—offer broader external validity and feasibility in less time and at lower cost. However, due to lack of random assignment, these studies are susceptible to measured and unmeasured confounding. Several techniques help mitigate these concerns, including a detailed pre-specified protocol, tools such as propensity score matching to balance measured confounders, falsification endpoint testing for assessing the presence of unmeasured confounders, and quasi-experimental designs (including instrumental variable analysis), which may be able to address both. Pre-specified sensitivity analyses and triangulation with complementary data sources further enhance robustness. Construct validity in observational CER depends on accurate patient profiling and validated computational phenotypes for identifying patients, exposures, and outcomes. Thoughtful study design and analytic rigor are essential for balancing these validity considerations. This brief review highlights these issues with examples from thrombosis research.
Adverse events of cold snare compared with hot snare and ablation endoscopic mucosal resection for large colorectal polyps
Medawar, Edgard , Pohl, Heiko , Rex, Douglas K. , Levenick, John M. , Pleskow, Douglas K. , Khashab, Mouen A. , Moyer, Matthew T. , Melson, Joshua , Wallace, Michael B. , Mosko, Jeffrey D. , Singh, Ajaypal , Gavrić, Aleksandar , Gordon, Stuart R. , Ngamruengphong, Saowanee , Taunk, Pushpak, Barber, Jeremy, Piraka, Cyrus , Elmunzer, B. Joseph , Aslanian, Harry R., Elatrache, Mazen, Zolotarevsky, Eugene, Rastogi, Amit , Renteln, Daniel von , Consortium, Additional members of the Large Polyp Study, Wallace, Michael B , Shahidi, Neal , Djinbachian, Roupen , von Renteln, Daniel , Pleskow, Douglas , Yang, Dennis J. , Djinbachian, Roupen , Consortium, Additional members of the Large Polyp Study

Endoscopy | July 24, 2025 | Volume: 58 | Issue: 02 | Pages: 163-173

10.1055/a-2665-0521 | PMID 40719106 Get It

Abstract Endoscopic mucosal resection (EMR) techniques for large (≥20 mm) nonpedunculated colorectal polyps (LNPCPs) have expanded with the introduction of ablation and cold EMR. This study assessed adverse events (AEs) for the newer EMR techniques, including cold EMR, compared with hot EMR. We conducted a secondary analysis of four prospective multicenter studies of consecutive patients with LNPCPs undergoing EMR from 2019 to 2024. The primary outcome was serious AEs (SAEs) with cold and hot EMR. Secondary outcomes included SAEs in the hot EMR subgroups (no ablation [hEMR], margin ablation [hEMR-m], margin and base ablation [hEMR-mb]). 1762 patients (mean age 65.8; 1890 LNPCPs) were included: 522 cold and 1368 hot EMRs (368 hEMR, 770 hEMR-m, 230 hEMR-mb). SAEs were higher with hot EMR (4.7%, 95%CI 3.6%–5.9%) vs. cold EMR (1.9%, 95%CI 0.9%–3.5%), also for the subgroups of hEMR (6.0%, 95%CI 3.8%–8.9%), hEMR-m (3.9%, 95%CI 2.6%–5.5%), and hEMR-mb (5.2%, 95%CI 2.7%–8.9%). Serious postendoscopic bleeding (PEB) was numerically higher with hot EMR (2.3%, 95%CI 1.6%–3.3%) vs. cold EMR (1.3%, 95%CI 0.5%–2.7%), also for the subgroups of hEMR (3.0%, 95%CI 1.5%–5.3%), hEMR-m (1.9%, 95%CI 1.1%–3.2%), and hEMR-mb (2.6%, 95%CI 1.0%–5.6%). Perforation, intraprocedural and post-procedural, was numerically higher with hot EMR (1.2%, 95%CI 0.7%–2.0%) vs. cold EMR (0.2%, 95%CI 0.0%–1.1%). hEMR-m and hEMR-mb with clipping had lower rates of serious and overall PEB than no clipping. Cold EMR demonstrated lower rates of SAEs, serious PEB, and perforation compared with hot EMR. Perforation and mortality occurred almost exclusively after hot EMR. Hot EMR with margin +/− base ablation did not increase SAEs compared with hot EMR without ablation.
Testosterone for the Treatment of Hypoactive Sexual Desire Disorder in Perimenopausal and Postmenopausal Women
Kling, Juliana M.

Obstetrics & Gynecology | July 24, 2025 | Volume: 146 | Issue: 3 | Pages: 341-349

10.1097/aog.0000000000006015 | PMID 40706034 Get It

Although there is no androgen deficiency diagnosis for women, research demonstrates that testosterone treatment can be modestly beneficial in treating appropriately selected postmenopausal women with distressing low desire, also known as hypoactive sexual desire disorder (HSDD). Current data do not support the role of testosterone treatment in supporting bone health or brain health or improving energy or cognition in women, and only limited research supports its benefit for HSDD treatment in women of late reproductive age. No current U.S. Federal Drug Administration–approved formulation of testosterone is available for women in the United States because of a lack of long-term safety data. However, two clinical guidelines now provide expert guidance on testosterone treatment and monitoring in women for HSDD. This narrative review presents the data and summarizes the guidelines in a clinically relevant format to make the information accessible to clinicians treating cisgender women with HSDD seeking testosterone treatment.
Real-world outcomes of brexucabtagene autoleucel for relapsed or refractory mantle cell lymphoma: a CIBMTR analysis
Ahmed, Nausheen , Kambhampati, Swetha , Hamadani, Mehdi , Hu, Zhen‐Huan , Grover, Natalie S. , Shadman, Mazyar , Locke, Frederick L. , Gerson, James N. , Frank, Matthew J. , Budde, Lihua E. , Wang, Michael , Bye, Matthew , Kharfan‐Dabaja, Mohamed A. , Sauter, Craig S. , Logan, Brent R., Nunes, Ana, Dalton, David , Kloos, Ioana , Xu, Hairong, Pasquini, Marcelo C. , Herrera, Alex F. , Thiruvengadam, Swetha Kambhampati , Grover, Natalie S , Gerson, James , Kim, Soyoung , Kharfan-Dabaja, Mohamed A , Hematti, Peiman , Turtle, Cameron J , Ahmed, Sairah , Moskop, Amy , Nunes, Ana , Dalton, David , Pasquini, Marcelo , Herrera, Alex F , Hamadani, Mehdi , Shadman, Mazyar , Ahmed, Nausheen , Locke, Frederick L , Kim, Soyoung , Hematti, Peiman , Turtle, Cameron J. , Ahmed, Sairah , Moskop, Amy , Lee, Daniel Y.

Blood Advances | July 24, 2025 | Volume: 9 | Issue: 20 | Pages: 5382-5396

10.1182/bloodadvances.2024015014 | PMID 40706035 Get It

Abstract Brexucabtagene autoleucel (brexu-cel) is a chimeric antigen receptor T-cell therapy approved for relapsed/refractory mantle cell lymphoma (R/R MCL). Here, we report real-world effectiveness and safety outcomes of brexu-cel in a prospective study of patients with R/R MCL, including subgroups based on prior treatment with Bruton's tyrosine kinase inhibitor, bendamustine, or autologous hematopoietic cell transplant (auto-HCT) and number of prior therapy lines, using Center for International Blood and Marrow Transplant Research registry data. A total of 476 patients with R/R MCL who received brexu-cel between July 2020 and December 2022 were included in the analysis. With a median follow-up of 13.5 months, the overall response rate was 91% and complete response rate was 82%. One-year overall survival and progression-free survival rates were 76% and 63%, respectively. One-year cumulative incidence of nonrelapse mortality was 8%. Prior auto-HCT was associated with better duration of response within 6 months after infusion (hazard ratio [HR], 0.49; 95% confidence interval [CI], 0.28-0.85) but greater risk of immune effector cell–associated neurotoxicity syndrome (odds ratio [OR], 1.66; 95% CI, 1.06-2.60). Prior bendamustine was associated with increased risk of prolonged thrombocytopenia (OR, 1.90; 95% CI, 1.13-3.21). In patients with 1 to 2 prior therapy lines, relapse or progression was less frequent compared with those with ≥3 prior lines (HR, 0.64; 95% CI, 0.42-1.00). Collectively, our results suggest that real-world outcomes with brexu-cel were consistent with those of the ZUMA-2 trial, regardless of prior therapy type or number of prior therapy lines.
Post-traumatic Triradiate Cartilage Physeal Bar Excision with 3D Navigation
Varas‐Rodríguez, Emil , Yuan, Brandon J. , Milbrandt, Todd A. , Grigoriou, Emmanouil , Yuan, Brandon

JBJS Case Connector | July 24, 2025 | Volume: 15 | Issue: 3 | Pages: No page available

10.2106/jbjs.cc.25.00177 | PMID 40705856 Get It

Case: An 8-year-old boy underwent open reduction and internal fixation for pelvic and femoral fractures following a crush injury. At nine months postoperatively, computed tomography demonstrated a triradiate physeal bar contralateral to operated hemipelvis. A navigated physeal bar excision with O-arm navigation and low-dose radiation protocol was performed. Conclusion: Triradiate bar excision presents a technically challenging procedure that may be offset by O-arm navigation utilization, which provides accurate, real-time imaging that facilitates complete physeal bar excision while mitigating risk of damage to surrounding structures. Our low-dose protocol yielded a total exposure of 0.914 mSv, comparable with 1.5 pelvic radiographs.
Cognitive impairment in cerebral venous congestion: The need for improved assessment tools – a literature review
Hui, Ferdinand , Ghozy, Sherief , Amans, Matthew R. , Brinjikji, Waleed , Abdalkader, Mohamad , Yedavalli, Vivek , Chyung, Abraham SC, Siddiqui, Adnan H. , Hui, Ferdinand , Amans, Matthew , Siddiqui, Adnan H , Ghozy, Sherief , Yedavalli, Vivek S , Chyung, Abraham S.C., Mendes Pereira, Vitor , Lenck, Stéphanie , Hillis, Argye Elizabeth , Fargen, Kyle M

Journal of NeuroInterventional Surgery | July 24, 2025 | Volume: 18 | Issue: 5 | Pages: 1401-1407

10.1136/jnis-2025-023392 | PMID 40707244 Get It

Objective Cognitive impairment is increasingly recognized in patients with cerebral venous congestion (CVC), yet the cognitive tools used are largely adapted from stroke and dementia research. This review examines current literature on cognitive function in CVC, including conditions such as cerebral venous sinus thrombosis (CVST), idiopathic intracranial hypertension (IIH), and dural arteriovenous fistulas (dAVFs). Special emphasis is placed on the limitations of common screening tools like the Montreal Cognitive Assessment (MoCA) and Mini-Mental State Examination (MMSE). Cognitive dysfunction—primarily affecting executive function, processing speed, and attention—is reported in up to 86% of CVC cases, yet only about 20% of studies use validated cognitive testing tools, most of which may lack sensitivity for CVC-specific deficits. Emerging techniques such as ocular motor testing and physiological markers show promise but require further validation. There is an urgent need for standardized, CVC-specific cognitive assessment protocols that reflect the unique pathophysiology of venous disorders. Future research should prioritize the development of targeted cognitive batteries and integrate objective physiological measures to enhance diagnostic accuracy.
Modified Proximal Gastrectomy and D2 Lymphadenectomy Is an Oncologically Sound Operation for Locally Advanced Proximal and GEJ Adenocarcinoma
Siegler, Emily L. , Grotz, Travis E. , Grotz, Travis E

Cancers | July 24, 2025 | Volume: 17 | Issue: 15 | Pages: 2455

10.3390/cancers17152455 | PMID 40805155 Get It

Background: Proximal gastrectomy (PG) with double tract reconstruction (DTR) offers organ preservation for early gastric cancers, leading to reduced vitamin B12 deficiency, less weight loss, and improved quality of life. The JCOG1401 study confirmed excellent long-term outcomes for PG in stage I gastric cancer. However, in locally advanced proximal gastric cancer (LAPGC), preserving the gastric body and lymph node station 4d may compromise margin clearance and adequate lymphadenectomy. Methods: We propose a modified PG that removes the distal esophagus, gastroesophageal junction (GEJ), cardia, fundus, and gastric body, preserving only the antrum and performing DTR. Lymphadenectomy is also adapted, removing stations 1, 2, 3a, 4sa, 4sb, 4d, 7, 8, 9, 10 (spleen preserving), 11, and lower mediastinal nodes (stations 19, 20, and 110), while preserving stations 3b, 5, and 6. Indications for this procedure include GEJ (Siewert type II and III) and proximal gastric cancers with ≤2 cm distal esophageal involvement and ≤5 cm gastric involvement. Results: In our initial experience with 14 patients, we achieved R0 resection in all patients, adequate lymph node harvest (median 24 nodes, IQR 18–38), and no locoregional recurrences at a median follow-up of 18 months. We also found favorable postoperative weight loss, reflux, and anemia in the PG cohort. Conclusion: While larger studies and long-term data are still needed, our early results suggest that modified PG—despite sparing only the antrum—retains the key benefits of PG over total gastrectomy, including better weight maintenance and improved hemoglobin levels, while maintaining oncologic outcomes for LAPGC.
Salvaging Proximal Pole Scaphoid Nonunions Using Ipsilateral Proximal Hamate Autograft: A Multicenter Case Series
Strother, Courtney Carlson , Elhassan, Bassem T. , Yao, Jeffrey , Gaston, R. Glenn , Kakar, Sanjeev , Carlson Strother, Courtney , Meaike, Joshua, Elhassan, Bassem, Gaston, R Glenn , Kakar, Sanjeev , Meaike, Joshua J. , Elhassan, Bassem T. , Kamal, Robin N.

HAND | July 24, 2025 | Volume: 21 | Issue: 8 | Pages: 1305-1311

10.1177/15589447251352002 | PMID 40704890 Get It

Background: Proximal pole scaphoid fracture nonunions are challenging conditions to treat. When significant comminution of the proximal pole and avascular necrosis is present, scaphoid proximal pole reconstructive options are considered. The proximal pole of the hamate is a local autograft option; however, little has been described on the outcomes of this procedure. Methods: Patients who underwent proximal pole scaphoid reconstruction using proximal hamate autograft at 3 tertiary care centers were retrospectively reviewed. Radiographic union was classified by greater than 50% bony trabeculae across the reconstruction site on computed tomography scan. Results: Ten patients were included. Average age at the time of surgery was 27.9 years, and 60% were men. Average length of proximal hamate autograft harvested was 10 mm. All patients healed at an average of 14.3 weeks following surgery. At final follow-up, 3 patients reported no pain, 3 reported mild occasional pain, 2 reported moderate tolerable pain (1 at the hamate graft site), and 2 had no reports on their pain level. Conclusions: In small proximal pole scaphoid nonunions with fragmentation and avascular necrosis, ipsilateral proximal hamate autograft reconstruction of the scaphoid proximal pole is a viable and reproducible option with high rates of union and patient satisfaction.